Abbott Laboratories [NYSE: ABT] price plunged by -1.23 percent to reach at -$1.51. The company report on April 12, 2021 that World’s Fastest Marathoner Eliud Kipchoge Uses Abbott’s Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games.
– Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons.
– Kipchoge and NN Running Team members will wear Abbott’s Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games.
A sum of 4722732 shares traded at recent session while its average daily volume was at 5.18M shares. Abbott Laboratories shares reached a high of $122.83 and dropped to a low of $121.285 until finishing in the latest session at $121.50.
The one-year ABT stock forecast points to a potential upside of 10.44. The average equity rating for ABT stock is currently 1.80, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $135.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 28, 2021. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on September 11, 2020, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $84, while Goldman analysts kept a Sell rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.14, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 6.16. The Price to Book ratio for the last quarter was 6.58, with the Price to Cash per share for the same quarter was set at 4.07. Price to Free Cash Flow for ABT in the course of the last twelve months was 67.40 with Quick ratio for the last quarter at 1.30.
ABT Stock Performance Analysis:
Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.16. With this latest performance, ABT shares gained by 2.88% in over the last four-week period, additionally plugging by 9.41% over the last 6 months – not to mention a rise of 36.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 54.70, with the RSI for the last a single of trading hit 56.15, and the three-weeks RSI is set at 54.09 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 120.90, while it was recorded at 121.25 for the last single week of trading, and 109.71 for the last 200 days.
Insight into Abbott Laboratories Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.
Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.
Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.70.
ABT Stock EPS
With the latest financial reports released by the company, Abbott Laboratories posted 0.65/share EPS, while the average EPS was predicted by analysts to be reported at 0.58/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 15.58%.
Abbott Laboratories [ABT] Insider Position Details
There are presently around $158,852 million, or 75.80% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 147,272,920, which is approximately -0.596% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 133,426,810 shares of the stock with an approximate value of $16.21 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $10.5 billion in ABT stock with ownership of nearly -1.166% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,197 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 41,940,673 shares. Additionally, 995 investors decreased positions by around 42,191,740 shares, while 336 investors held positions by with 1,223,289,994 shares. The mentioned changes placed institutional holdings at 1,307,422,407 shares, according to the latest SEC report filing. ABT stock had 241 new institutional investments in for a total of 4,101,178 shares, while 62 institutional investors sold positions of 3,473,300 shares during the same period.